Dr. Brad McGregor

This week on the Backtable Podcast.

We are talking now about a potential to cure patients, right?

And, you know, if we can offer intervention early on and cure patients, a defined course of therapy, despite the amazing results we have for comedy, say, ED, PEM, or the metastatic setting, it's still going to be better to offer that.

And so, it really is critical now, perioperative therapy.

Immunotherapy and chemotherapy, be it cisplatin per the NAGA regimen or EV in the more recent EV303 data, is really a standard of care.

And all patients should have the opportunity to discuss that.

Yeah, excited to be here.

I'm Brad McGregor.

I'm at Dana-Farber in Boston, where we have less snow than Cleveland right now.

Amanda?

I mean, I think it's changing at a rapid pace.

And I think it used to be we had data.

I mean, go back at some initial data, SWOG trials from the 90s, early 2000s, where it showed that neoadjuvant

dose-dense MVAC improved overall survival.

We had meta-analysis, about a 5% improvement in five-year-old survival with aggressive cisplatin neoadjuvant-based chemotherapy.

Added cisplatin-based therapy didn't work, right?

So in this situation where if a patient was LF cisplatin, they really should be getting neoadjuvant cisplatin-based therapy because it's hard to give cisplatin-based chemotherapy.

chemotherapy, but that's about half of the patients.

I mean, patients with bladder cancer are sick.

They're older, comorbidities, poor renal function.